» Articles » PMID: 40061704

Clinical Outcomes and Stroke Recurrence in Moyamoya Disease Post-Revascularization: A Retrospective Analysis

Overview
Specialty Pharmacology
Date 2025 Mar 10
PMID 40061704
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study aimed to assess the clinical characteristics, treatment outcomes, and recurrence risks in moyamoya disease (MMD) patients, focusing on the impact of revascularization and antiplatelet therapy.

Materials And Methods: Forty-six MMD patients were analyzed. Data on demographics, clinical characteristics, treatment outcomes, and recurrence rates of ischemic and hemorrhagic strokes were collected. The effectiveness of revascularization and the role of antiplatelet therapy in preventing recurrent strokes were statistically evaluated.

Results: The mean age was 19.5 years. Right-side weakness (28.3%) and left-side weakness (21.7%) were common symptoms. Pre-revascularization, recurrent ischemic strokes affected 58.7% of patients; post-revascularization, the incidence dropped to 8.7%. However, a high recurrence rate (39.1%) persisted among those not undergoing surgery. Post-revascularization hemorrhagic strokes were rare (6.5%). Antiplatelet therapy significantly reduced ischemic stroke recurrence ( < 0.001) and hemorrhagic stroke risk.

Conclusion: Early intervention and continuous antiplatelet therapy are crucial in managing MMD. Despite reduced ischemic stroke recurrence post-revascularization, functional outcomes often remained unimproved, indicating the need for optimized treatment strategies.

References
1.
Kao H, Hung C, Li H, Yeh C, Huang C, Chen Y . Long-term Outcomes After Endovascular Recanalization in Patients with Chronic Carotid Artery Occlusion. Am J Cardiol. 2018; 122(10):1779-1783. DOI: 10.1016/j.amjcard.2018.07.049. View

2.
Choi W, Lee S, Kim D, Huh P, Yoo D, Lee T . Thirteen-year Experience of 44 Patients with Adult Hemorrhagic Moyamoya Disease from a Single Institution: Clinical Analysis by Management Modality. J Cerebrovasc Endovasc Neurosurg. 2013; 15(3):191-9. PMC: 3804657. DOI: 10.7461/jcen.2013.15.3.191. View

3.
Chong P, Ogata R, Kobayashi H, Koizumi A, Kira R . Early onset of moyamoya syndrome in a Down syndrome patient with the genetic variant RNF213 p.R4810K. Brain Dev. 2014; 37(8):822-4. DOI: 10.1016/j.braindev.2014.12.006. View

4.
Amlie-Lefond C, Zaidat O, Lew S . Moyamoya disease in early infancy: case report and literature review. Pediatr Neurol. 2011; 44(4):299-302. DOI: 10.1016/j.pediatrneurol.2010.10.016. View

5.
Sato Y, Kazumata K, Nakatani E, Houkin K, Kanatani Y . Characteristics of Moyamoya Disease Based on National Registry Data in Japan. Stroke. 2019; 50(8):1973-1980. DOI: 10.1161/STROKEAHA.119.024689. View